Companies › Relay Therapeutics
2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Other; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zovegalisib (RLY-2608) PIK3CA inhibitor | PIK3CA | Phase 3 | PIK3CA Mutation; PIK3CA-Related Overgrowth Spectrum (PROS) | Apr 2027 |
| RLY-8161 NRAS-selective inhibitor | NRAS | Phase 1 | Advanced NRAS-Mutant Melanoma | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05216432 | Zovegalisib (RLY-2608) | Phase 1 | PIK3CA Mutation | Oncology | Apr 2027 |
| NCT06982521 | Zovegalisib (RLY-2608) | Phase 3 | PIK3CA Mutation | Oncology | Apr 2028 |
| NCT07584226 | RLY-8161 | Phase 1 | Advanced NRAS-Mutant Melanoma | Oncology | May 2029 |
| NCT06789913 | Zovegalisib (RLY-2608) | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS) | Other | Jul 2031 |
Cash of $124m on 2026-09-30; operating cash outflow about $227m a year; runway about 7 months at that burn, to Apr 2027; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Aura Biosciences Haihe Biopharma Immuneering Tyra Biosciences UroGen Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.